GlassScriptPhysician profile
Rose Cuneo
NPI 1083010318
$3,094.59
in general payments reported to CMS, 2019-2025
22 companies · $503 in 2025
The $503 reported for 2025 was more than what 75% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $500 · 2022: $831 · 2023: $915 · 2024: $346 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,763.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $394.29 | 2021-2024 | Farxiga, Breztri |
| Vanda Pharmaceuticals INC. | $347.97 | 2021-2025 | Fanapt |
| Abbvie INC. | $277.94 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $271.28 | 2021-2022 | |
| Alkermes, INC. | $220.93 | 2021-2023 | Lybalvi, Aristada, Vivitrol |
| Novo Nordisk INC | $218.26 | 2025 | Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $200.18 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $166.35 | 2021-2023 | Austedo |
| Lilly USA, LLC | $114.62 | 2021-2023 | Mounjaro |
| Glaxosmithkline, LLC. | $109.42 | 2022-2023 | Trelegy Ellipta |
| Amgen INC. | $103.48 | 2023 | Repatha |
| Lundbeck LLC | $100.76 | 2021-2024 | Rexulti |
| Astellas Pharma US INC | $98.95 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.75 | 2021 | |
| Janssen Pharmaceuticals, INC | $86.58 | 2022-2025 | Invega Sustenna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $77.39 | 2021-2024 | Abilify Maintena, Rexulti |
| Gilead Sciences, INC. | $67.32 | 2022-2025 | |
| Axsome Therapeutics, INC. | $47.05 | 2024 | Auvelity |
| Viiv Healthcare Company | $33.03 | 2022-2023 | Apretude |
| Takeda Pharmaceuticals U.S.A., INC. | $26.75 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $22.04 | 2025 | Pifeltro |
| Bayer Healthcare Pharmaceuticals INC. | $14.25 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Cuneo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.